Profound Medical (PROF) Projected to Post Earnings on Thursday

Key Points

• Profound Medical is expected to release its Q2 2025 earnings on August 14, forecasting a loss of ($0.43) per share and revenue of $4.75 million.
• CEO Arun Swarup Menawat recently purchased over 12,000 shares of the company, increasing his holdings by 2.09%, which suggests confidence in the company's future.
• The stock has experienced notable volatility, with a 1-year high of $10.25 and a low of $3.89, and currently has a market capitalization of approximately $165.58 million.

Profound Medical (NASDAQ:PROF - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data after the market closes on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.43) per share and revenue of $4.75 million for the quarter.

Profound Medical (NASDAQ:PROF - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Profound Medical had a negative return on equity of 70.41% and a negative net margin of 269.35%. The business had revenue of $2.62 million during the quarter, compared to analysts' expectations of $4.78 million. On average, analysts expect Profound Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Profound Medical Stock Down 2.3%

Shares of PROF traded down $0.13 during mid-day trading on Friday, hitting $5.54. The company's stock had a trading volume of 22,635 shares, compared to its average volume of 31,252. The company's 50-day moving average is $5.93 and its 200-day moving average is $5.86. Profound Medical has a 52-week low of $3.89 and a 52-week high of $10.25. The firm has a market capitalization of $166.48 million, a price-to-earnings ratio of -4.54 and a beta of 0.52. The company has a current ratio of 11.31, a quick ratio of 10.03 and a debt-to-equity ratio of 0.09.

Analyst Upgrades and Downgrades

PROF has been the subject of a number of analyst reports. Raymond James Financial cut shares of Profound Medical from a "strong-buy" rating to a "moderate buy" rating in a research report on Friday, May 9th. Lake Street Capital decreased their target price on shares of Profound Medical from $17.00 to $11.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd.

Insider Activity

In related news, CEO Arun Swarup Menawat purchased 12,027 shares of the firm's stock in a transaction on Friday, May 16th. The stock was acquired at an average price of $4.73 per share, with a total value of $56,887.71. Following the completion of the acquisition, the chief executive officer owned 587,089 shares in the company, valued at approximately $2,776,930.97. This represents a 2.09% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 1.52% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Profound Medical stock. Royal Bank of Canada grew its stake in Profound Medical (NASDAQ:PROF - Free Report) by 3.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 435,997 shares of the company's stock after buying an additional 14,795 shares during the period. Royal Bank of Canada owned 1.45% of Profound Medical worth $2,537,000 at the end of the most recent quarter. 47.86% of the stock is currently owned by institutional investors and hedge funds.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.